Document is current

Article History

Received: 25 September 2020

Revised: 19 March 2021

Accepted: 6 April 2021

First Online: 27 April 2021

Compliance with ethical standards

:

: RRF has been a consultant for Pharmacyclics, Janssen Biotech, Genentech/Roche, Sunesis Pharmaceuticals, Loxo, TG Therapeutics, Verastem, Acerta Pharma, AstraZeneca, BeiGene, Incyte, OncoTracker, and AbbVie; has received reimbursement for travel, accommodations, and expenses from TG Therapeutics and Janssen Oncology; has provided expert testimony for AbbVie and Janssen Oncology; has received honoraria from Janssen and Genentech/Roche; has received research funding from Acerta Pharma and TG Therapeutics; and reports “other relationship” for Incyte, Janssen Biotech, and AbbVie. JCB has received research funding from Acerta Pharma, Genentech, Janssen, and Pharmacyclics. RGO has been a consultant for Acerta Pharma, BeiGene, Janssen, and Celgene, and has received honoraria from AstraZeneca, Janssen, BeiGene, Celgene, and Takeda. SMO is employed by the University of California, Irvine; has been a consultant for Amgen, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Vaniam Group, AbbVie/Genentech, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Astellas Pharma, Gilead Sciences, Pharmacyclics, TG Therapeutics, Pfizer, Verastem, Eisai, Juno Therapeutics, and Vida Ventures; has received reimbursement for travel, accommodations, and expenses from Celgene, Janssen, Gilead Sciences, Regeneron, and Janssen Oncology; has received honoraria from Celgene, Janssen, Pharmacyclics, Gilead Sciences, Pfizer, Amgen, Astellas Pharma, GlaxoSmithKline, Aptose Biosciences, Vaniam Group, AbbVie, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Loxo, Eisai, and TG Therapeutics; and has received research funding (to institution) from Acerta Pharma, Regeneron, Gilead Sciences, Pfizer, TG Therapeutics, Pharmacyclics, Kite Pharma, and Sunesis Pharmaceuticals. JRB has been a consultant for AbbVie, Acerta, AstraZeneca, BeiGene, Catapult, Dynamo, Eli Lilly, Genentech/Roche, Gilead, Juno/Celgene, Kite, Loxo, MEI Pharma, Nextcea, Novartis, Octapharma, Rigel, Pfizer, Pharmacyclics, Redx, Sun, Sunesis, TG Therapeutics, and Verastem; has received honoraria from Janssen and Teva; has received research funding from Gilead, Loxo, Sun, and Verastem; and is on Data Safety Monitoring Committees for Morphosys and Invectys. PH has been a consultant for AbbVie, Acerta Pharma, Alexion Pharmaceuticals, Gilead, and Janssen; has received honoraria from AbbVie, Acerta Pharma, Alexion Pharmaceuticals, Gilead, and Janssen; and has received research funding from AbbVie, Gilead, Janssen, GlaxoSmithKline, Pharmacyclics, and Roche. DMS has been a consultant for Pharmacyclics/Janssen, Karyopharm, BeiGene, and Innate; has received honoraria from Genentech; and has received research funding from Acerta Pharma, Gilead Sciences, Karyopharm Therapeutics, Verastem, and Juno Therapeutics. TL, PP, and MB are employees of Acerta Pharma (a member of the AstraZeneca Group) and may or may not have equity ownership in Acerta Pharma and/or AstraZeneca. AMH and RI were employees of Acerta Pharma (a member of the AstraZeneca Group) at the time of this study, are patent holders, and have equity ownership in Acerta Pharma and/or AstraZeneca. NC was an employee of Acerta Pharma (a member of the AstraZeneca Group) at the time of this study. BC has received research funding from Acerta, Celgene, Genentech, Merck, Millennium, MorphoSys, F Hoffman-La Roche, Triphase, and Seattle Genetics, and has been a consultant on advisory boards for Verastem, Seattle Genetics, and AstraZeneca. MJSD has been a consultant for Sandoz, has participated in speakers bureaus for Teva, and has received research funding (Institution) from Gilead Sci, AstraZeneca, Astex Pharma, Bioinvent, and Roche. CS has received research funding from Genmab. SR is an employee and stockholder of VelosBio; has received research funding from Janssen, and has served on advisory boards for Janssen Kite. MW has been a consultant for Pharmacyclics, Celgene, Janssen, AstraZeneca, MoreHealth, Pulse Biosciences, Nobel Insights, Guidepoint Global, Kite Pharma, Juno, Loxo Oncology, InnoCare, and Oncternal; has received research funding from Janssen, AstraZeneca, Acerta Pharma, Pharmacyclics, Juno Therapeutics, Celgene, Kite Pharma, Loxo Oncology, VelosBio, Verastem, Molecular Templates, BioInvent, and Oncternal; has received honoraria from Pharmacyclics, Janssen, AstraZeneca, OMI, Targeted Oncology, OncLive, Dava Oncology, Beijing Medical Award Foundation, and Lu Daopei Medical Group; and has received reimbursement for travel, accommodations, and expenses from Janssen, Pharmacyclics, Celgene, OMI, Kite Pharma, and AstraZeneca. PG has received consulting/advisory fees/honoraria from Acerta Pharma/AstraZeneca, AbbVie, BeiGene, Janssen, Gilead Sci, Sunesis Pharma, Juno Therapeutics, ArQule, Adaptive Bio, Dynamo Therapeutics, and MEI Pharma; and has received research funding from AbbVie, Janssen Oncology, Gilead Sci, Sunesis Pharma, and Novartis. WJ is employed by the Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland; and has received research funding from Acerta, Bayer, BeiGene, Janssen, MeiPharma, Merck, Pharmacyclics, Roche, Takeda, and TG Therapeutics. JMP has been a consultant for Pharmacyclics, Gilead Sciences, AstraZeneca, and Actinium Pharmaceuticals. JPS has been a consultant for and has received research funding from AstraZeneca, AbbVie, Pharmacyclics, Genentech, TG Therapeutics, BeiGene, and Pfizer. The other author declares no competing interests.